Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.24.1.u1
Segment Information (Tables)
3 Months Ended
Mar. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Information
The following tables present the Company's segment information for the 13 weeks ended March 30, 2024 and April 1, 2023 (in $000's):
Thirteen Weeks Ended
March 30, 2024 April 1, 2023
Revenues
Biotechnology $ —  $ — 
Discontinued operations —  3,795 
Total Revenues $ —  $ 3,795 
Gross profit
Biotechnology $ —  $ — 
Discontinued operations —  (197)
Total Gross profit $ —  $ (197)
Operating loss
Biotechnology $ (1,806) $ (1,099)
Discontinued operations —  14,158 
Total Operating loss $ (1,806) $ 13,059 
Depreciation and amortization
Biotechnology $ —  $ 364 
Discontinued operations —  96 
Total Depreciation and amortization $ —  $ 460 
Interest (income) expense, net
Biotechnology $ 252  $ (475)
Discontinued operations —  181 
Total Interest expense, net $ 252  $ (294)
Net income (loss) before income taxes
Biotechnology $ (2,219) $ (889)
Discontinued operations —  13,976 
Total Net income before income taxes $ (2,219) $ 13,087